Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Bone Marrow Transplantation|January 26, 2006
Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantationC-K Lee, M Zangari, A Fassas, et al.
Blood|August 25, 2001
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyM Zangari, E Anaissie, B Barlogie, et al.
Blood Cancer Journal|January 3, 2015
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center studyA J Greenberg, S Philip, A Paner, et al.
Bone Marrow Transplantation|October 28, 2003
Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cellsA P Rapoport, B L Levine, A Badros, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 11, 2002
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsM Zangari, F Saghafifar, E Anaissie, et al.
Blood|July 4, 2001
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsB Barlogie, R Desikan, P Eddlemon, et al.
Bone Marrow Transplantation|December 12, 2002
Transplantation as salvage therapy for high-risk patients with myeloma in relapseC-K Lee, B Barlogie, M Zangari, et al.
British Journal of Haematology|September 21, 2001
Results of autologous stem cell transplant in multiple myeloma patients with renal failureA Badros, B Barlogie, E Siegel, et al.
British Journal of Haematology|February 13, 2001
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor aloneK R Desikan, G Tricot, N C Munshi, et al.
Blood|April 21, 2001
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsA Badros, B Barlogie, C Morris, et al.
Pageof 3